BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update
09 août 2023 06h30 HE
|
BiomX
Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates FDA grants BX004 Fast Track designation Initial Data from Part 2 Now...
BiomX to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 9th, 2023
02 août 2023 16h30 HE
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...
NYSE American Initiates Delisting Proceedings for BiomX Warrants
08 juin 2023 17h00 HE
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, June 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...
BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Conference (ECFC)
31 mai 2023 03h00 HE
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...
BiomX Reports First Quarter 2023 Financial Results and Provides Business Update
15 mai 2023 06h30 HE
|
BiomX
Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”); Results from Part 2 Expected in Third Quarter of 2023 Second...
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
12 mai 2023 08h00 HE
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...
BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023
08 mai 2023 06h30 HE
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...
BiomX Announces Second Closing of $7.5 Million Private Placement
05 mai 2023 06h30 HE
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered...
BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
29 mars 2023 06h30 HE
|
BiomX
Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (“CF”) Patient Enrollment Continues in Part 2 of Phase 1b/2a Trial...
BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023
27 mars 2023 07h00 HE
|
BiomX
CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and...